VC firms
Mission Bay Capital LLC uses capital and expertise to help entrepreneurs emerging from the University of California change the world. We begin with the conviction that more of the creativity of the University of California can directly benefit society. Universities have an obligation to meet public needs for new sources of energy, new solutions for patients, and ultimately the formation of whole new industries.
MBC will help launch companies that meet these needs. Our success will redress social challenges, replenish future funds, and ultimately build a research and educational endowment for QB3 (California Institute for Quantitative Biosciences) to drive the development of the next generation of innovations.
MBC will help launch companies that meet these needs. Our success will redress social challenges, replenish future funds, and ultimately build a research and educational endowment for QB3 (California Institute for Quantitative Biosciences) to drive the development of the next generation of innovations.
Overview
Location
United States, California, San Francisco
Employees
1-10
Founded date
2009
Investment Type
Venture Capital
Investment Stage
Pre-Seed; Seed; Series A
Funds raised 2
| Date | Fund size | Announcement |
| Sign up to see | Sign up to see | Sign up to see |
| May 12, 2015 | $25M | Mission Bay Capital Closes $25M Life Sciences Fund |
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 22, 2021 | Plant-based cheesemaker Nobell Foods nets $75m from a16z, AgFunder & Breakthrough Energy | Disclosure: AFN’s parent company AgFunder is an investor in Nobell Foods. Alt-protein startup Nobell Foods has raised $75 million in a Series B round led by Breakthrough Energy Ventures (BEV) – the climate-focused investment group founded b... |
| Sep 17, 2019 | Life science-focused Mission Bay Capital raises $60m for Fund III | San Francisco-based VC Mission Bay Capital has raised $60m for the final close of its third early-stage life-science fun |
| Sep 16, 2019 | Mission Bay Capital Closes Fund III, at $60M | Mission Bay Capital, a San Francisco, CA-based early-stage life-science venture capital firm investing in innovative entrepreneurs working on vital medical and environmental challenges, closed its third fund, at $60M. Investors include Aste... |
| Dec 5, 2017 | Asilomar Bio Raises $12m Series B for Chemical Yield Enhancer | Asilomar Bio, a San Francisco-based maker of chemical crop inputs has raised a $12.25 million Series B Round to bring it’s first chemical yield enhancement product to market. This announcement comes on the heels of a licensing agreement wit... |
| Sep 8, 2016 | Chrono Therapeutics raises $47.6M for smoking cessation wearable to deliver nicotine fix before you wake | The wearable also has a “crave” button users can press that records the moment they want a cigarette and triggers an immediate coaching message through the app to help the user get through the moment without smoking. There is also a behavio... |
| May 12, 2015 | Mission Bay Capital Closes $25M Life Sciences Fund | Mission Bay Capital, LLC (MBC), a San Francisco, CA-based seed-stage venture firm investing in life science companies emerging from the University of California and the San Francisco Bay Area ecosystem, closed its latest fund at $25m. Inves... |
| May 20, 2013 | eFFECTOR Therapeutics Raises $45 Million in Series A Financing | eFFECTOR Therapeutics Raises $45 Million in Series A Financing Company to Focus on Small Molecule Selective Regulators of Protein Synthesis for Cancer San Diego, CA – May 20, 2013 – eFFECTOR Therapeutics, a newly established biopharmaceutic... |
| May 20, 2013 | eFFECTOR Therapeutics Completes $45M Series A Financing | eFFECTOR Therapeutics, a San Diego, CA-based newly formed biopharmaceutical company, completed a $45m Series A financing. Backers included U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage... |
| Chrono Therapeutics raises $47.6M for smoking cessation wearable to deliver nicotine fix before you wake | Smoking cessation is a big priority for self-insured employer programs and payers, particularly since most payers are inclined to reimburse for these programs because of the impact of smoking on health. The challenge, as Chrono Therapeutics... |
Reviews 0
FAQ about Mission Bay Capital
When was Mission Bay Capital founded?
Mission Bay Capital was founded in 2009.
What funds has Mission Bay Capital raised?
Mission Bay Capital has announced 2 funds on Parsers VC, among them a $25M fund on May 12, 2015.
What has the press written about Mission Bay Capital?
Parsers VC has collected 10 articles mentioning Mission Bay Capital, among them “Plant-based cheesemaker Nobell Foods nets $75m from a16z, AgFunder & Breakthrough Energy” (Jul 22, 2021) and “Life science-focused Mission Bay Capital raises $60m for Fund III” (Sep 17, 2019).
Is Mission Bay Capital still active?
Yes, Mission Bay Capital is active; its latest activity on Parsers VC dates from Mar 11, 2024.